【直报网4月13日讯】（参考消息网）日本药企在推动在华生产，向中国市场投放最新产品。具有领先优势的欧美企业则努力增加能与发达国家“零时差”上市的产品。

CNDSN (Reference News Network April 13th News Network) Japanese pharmaceutical companies in the promotion of production in China to launch the new products to the Chinese market. The leading edge of the European and American companies are trying to increase with the developed countries "Zero Day" listing of products.

外媒称，美国、日本和欧洲的大型制药企业正在以主力药物为武器猛攻中国市场。

Foreign media said the United States, Japan and Europe, the large pharmaceutical companies are the main drugs for weapons stormed the Chinese market.

日经中文网4月10日报道，日本药企在推动在华生产，同时向中国市场投放最新产品。具有领先优势的欧美企业则通过在华设置研究基地等，努力增加能与发达国家“零时差”上市的产品。以经济增长和人口老龄化为背景，中国的医药品市场已扩大至仅次于美国的全球第二大规模。随着发达国家市场增长放缓，各企业都在急于转向中国，但是开拓市场似乎必须出奇制胜。

The Nikkei Chinese network reported on April 10th, the Japanese pharmaceutical companies in the promotion of production in China, at the same time to launch the new products to the Chinese market. The leading edge of the European and American enterprises in China through setting the research base, efforts to increase with the developed countries "Zero Day" listing of products. With the economic growth and the aging of the population as the background, the Chinese pharmaceutical market has been expanded to the world's second largest after the United States. With the developed countries, the market slowdown, companies are eager to turn to China, but the market seems to be a surprise move.

质检提前生产3年

Quality in production for 3 years

日本药品企业卫材2014年年末在江苏省苏州市新建了占地达13万平方米的战略工厂。在这里，用特殊摄像头检查药品的实验已经开始。在一个圆盘上装有40只药瓶，每只玻璃药瓶高6厘米、直径1厘米。圆盘转动，光束逐一照射玻璃瓶。特殊摄像头可以分析药瓶被光照产生的影子，确定其中有无异物混入。

The Japanese pharmaceutical companies Eisai in late 2014 in Suzhou city of Jiangsu province for new strategic space of 130000 square meters factory. Here, using a special camera inspection of drug experiment has begun. There are 40 bottles in a disk on each glass vial, high 6 cm, 1 cm in diameter. Rotating disk, one glass bottle beam irradiation. Special cameras can analyze bottle by light shadow, there are no contamination.

被检测的药品名为弥可保，是一种缓和由糖尿病引发的手足麻木的注射药剂。这是卫材公司的主力产品之一，现在仅在日本生产。因为要在中国申请药物生产许可，所以工厂预计到2018年才能投产，但为了保证万无一失，从日本派来的工作人员已经开始全力调试检测设备。

The drug was detected for mecobalamin injection, is a moderated by brothers coma caused by diabetes. This is one of the main products of the Eisai Co, now only in japan. Because of the need to apply for drug production license in China, so the plant is expected to be put into operation in 2018, but in order to ensure safety, the Japanese sent workers have begun to debugging and testing equipment.

中国市场超过日本跃居世界第二

China surpassed Japan ranked second in the world

中国的糖尿病患者据推测达1.2亿人，而且还在不断增加。目前，有2/3的弥可保销往中国。通过在中国生产，卫材将把弥可保的供应量翻一番，达到每年4000万瓶。卫材的中国法人卫材投资的兼古宪生董事长表示，这将能够迅速弥补此前市场供应的缺口。

Patients with diabetes Chinese presumably up to 120000000 people, and is still increasing. At present, there are 2/3 to China methycobal. Through the Chinese production, Eisai will supply the mecobalamin doubled, reaching an annual 40000000 bottles. China Investment Corporation Eisai Eisai's and ancient Xian Sheng said the chairman of the board, which will be able to quickly make up for the previous market supply gap.

卫材还将追加投资76亿日元，建设生产片剂的新厂房。将生产治疗阿尔茨海默症(俗称“痴呆症”)的药品安理申等主力药物。年产能力也将翻一番，增至50亿片。力争2018年度把在中国的销售额提高为现在的两倍，达到800亿日元。

Eisai also will invest an additional 7600000000 yen, the construction of the new workshop production of tablets. The production of the treatment of Alzheimer's disease (commonly known as "dementia") the main drug drug aricept. Annual output capacity will be doubled, to 5000000000. Strive to 2018 annual sales in China increased to two times now, to reach 80000000000 yen.

美国调查公司IMS Health称，2013年中国的医药品市场已达到977亿美元，市场规模超过日本位列世界第2位。到2018年规模最大将达1850亿美元，接近现在的两倍。

The United States survey firm IMS Health said that in 2013 China's pharmaceutical market has reached $97700000000, the market size of over Japan ranked second in the world. In 2018 the largest scale will reach $185000000000, nearly two times now.

必须在华研发和制药的原因

The reason to research and development in China and the pharmaceutical

而中国的药品市场还有其特有的问题。那就是在中国获得管理部门的药品许可的耗时较长，手续也更繁琐。此外中国各地的药品销售结构各有其复杂性，全国有1万3千家左右的医药品批发商，开拓医疗机构也非易事。

China's pharmaceutical market and the specific problems. It is in China to obtain approval of the Department of management procedures are more cumbersome and time-consuming. In addition, drug sales Chinese structure around each has its complexity, there are 10000 about 3000 pharmaceutical wholesalers across the country, develop the medical institutions will not be easy.

欧美企业凭借其强大的财力在推进对策。法国赛诺菲2014年在上海设立了亚洲研究基地。赛诺菲愿意承担成本也要保证和发达国家同步进行临床试验，这样可以保证主力新药可以和日本基本同步上市。

Europe and the United States by virtue of its strong financial enterprises in promoting countermeasures. France's Sanofi was set up in 2014 by the Asian Research Base in Shanghai. Senofi is willing to bear the cost of the developed countries but also to ensure the synchronization and clinical trials, which can ensure the main drug and Japan almost simultaneous listing.

在这样的竞争背景下，日本企业也通过投放主力药等开拓中国市场。安斯泰来制药将力争于2020年在中国发售其2014开始在日本发售的治疗前列腺癌的药品XTANDI，目前已经开始了临床试验。公司将在2019年年末之前将营销人员增加到1千多人，增加了25%。

In such a competitive background, Japanese companies have put through the main medicine to develop the Chinese market. The government of Tailai pharmaceutical will strive to go on sale in 2020 for treatment of prostate cancer in Japan at the beginning of the 2014 drugs in China XTANDI, has begun a clinical trial. The company will be in 2019 before the end of the year will be increased to more than 1 people in the marketing personnel, an increase of 25%.

第一三共也计划将在2017年前在中国发售两种药品，其中包括可以降低脑中风风险的抗凝血药依度沙班(edoxaban)，同时将营业人员也增加20%，增至800人。

Daiichi Sankyo also plans to offer two kinds of drugs in China in 2017, which can reduce the risk of stroke in the anti clotting drug according to Shaaban (edoxaban), at the same time, the sales staff also increased by 20% to 800 people.

在中国，生活习惯病和癌症患者的增加为日本制药企业提供了商机，但是在中国开拓市场也绝非易事。▲

In China habits, increased disease and cancer patients provided opportunities for Japanese companies, but in the China market development is not easy. "

（原标题：美欧日药企猛攻中国市场 质检提前生产3年）

(original title: the United States and Europe, a Chinese market ahead of production quality inspection companies 3 years)

责任编辑：小申

Editor: small Shen